Harnessing the power of the immune system to target cancer

Annual Review of Medicine

Volumn 64, Issue , 2013, Pages 71-90

  Lizee, Gregory ^a   Overwijk, Willem W ^a   Radvanyi, Laszlo ^a   Gao, Jianjun ^b   Sharma, Padmanee ^b   Hwu, Patrick ^a  

^a Center for Cancer Immunology Research   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

adoptive transfer; immune checkpoint blockade; immunotherapy; T cells; vaccines

Indexed keywords

CANCER VACCINE; CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; DACARBAZINE; IMATINIB; IMIQUIMOD; IMMUNOSTIMULATING AGENT; IPILIMUMAB; NIVOLUMAB; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; VEMURAFENIB;

ACTINIC KERATOSIS; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CELL TRANSFER; COLITIS; COLORECTAL CANCER; CYTOKINE RELEASE; DERMATITIS; DRUG SAFETY; GENE MUTATION; HEPATITIS; HUMAN; HYPOPITUITARISM; IMMUNE DEFICIENCY; IMMUNE RELATED ADVERSE EVENT; IMMUNE SYSTEM; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT LENTIGO; MELANOMA; MOLLUSCUM CONTAGIOSUM; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SKIN DISEASE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; VERRUCA VULGARIS;

CANCER VACCINES; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; NEOPLASMS;

EID: 84873023311     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-112311-083918     Document Type: Review

References (105)

1. Gresser I. 1987. A. Chekhov, M.D., and Coley's toxins. N. Engl. J. Med. 317:457
2. Coley WB. 1893. The treatment of malignant tumors by repeated inoculations of Erysipelas, with a report of ten original cases. Am. J. Med. Sci. 105:487-511
3. Lamm DL, Blumenstein BA, Crawford ED, et al. 1991. A randomized trial of intravesical doxorubicin and immunotherapywith bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N. Engl. J. Med. 325:1205-9
4. Rosenberg SA, Lotze MT. 1986. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu. Rev. Immunol. 4:681-709
5. Fyfe G, Fisher RI, Rosenberg SA, et al. 1995. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13:688-96
6. Atkins MB, Lotze MT, Dutcher JP, et al. 1999. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17:2105-16
7. Future II Study Group. 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356:1915-27
8. Rosenberg SA, Yang JC, Restifo NP. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10:909-15
9. Kantoff PW, Higano CS, Shore ND, et al. 2010. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363:411-22
10. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. 2010. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28:1099-105
11. Schwartzentruber DJ, Lawson DH, Richards JM, et al. 2011. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364:2119-27
12. Kenter GG, WeltersMJ, Valentijn AR, et al. 2009. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361:1838-47
13. Schuster SJ, Neelapu SS, Gause BL, et al. 2011. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29:2787-94
14. Brody JD, Ai WZ, Czerwinski DK, et al. 2010. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J. Clin. Oncol. 28:4324-32
15. Kim YH, Gratzinger D, Harrison C, et al. 2012. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood 119:355-63
16. Matsushita H, Vesely MD, Koboldt DC, et al. 2012. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482:400-4
17. Iwasaki A, Medzhitov R. 2010. Regulation of adaptive immunity by the innate immune system. Science 327:291-95
18. Banchereau J, Steinman RM. 1998. Dendritic cells and the control of immunity. Nature 392:245-52
19. Geisse J, Caro I, Lindholm J, et al. 2004. Imiquimod 5%cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J. Am. Acad. Dermatol. 50:722-33
20. Schulze HJ, Cribier B, Requena L, et al. 2005. Imiquimod 5%cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br. J. Dermatol. 152:939-47
21. Tran H, Moreno G, Shumack S. 2004. Imiquimod as a dermatological therapy. Expert Opin. Pharmacother. 5:427-38
22. Gollnick H, Barona CG, Frank RG, et al. 2005. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5- year follow-up study in Europe. Eur. J. Dermatol. 15:374-81
23. Dummer R, Hauschild A, Becker JC, et al. 2008. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin. Cancer Res. 14:856-64
24. Dudek AZ, Yunis C, Harrison LI, et al. 2007. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin. Cancer Res. 13:7119-25
25. PashenkovM, Goess G, Wagner C, et al. 2006. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol. 24:5716-24
26. Thompson JA, Kuzel T, Drucker BJ, et al. 2009. Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin. Genitourin. Cancer 7:E58-65
27. Hofmann MA, Kors C, Audring H, et al. 2008. Phase 1 evaluation of intralesionally injected TLR9- agonist PF-3512676 in patients with basal cell carcinoma ormetastaticmelanoma. J. Immunother. 31:520-27
28. Lou Y, Liu C, Lizee G, et al. 2011. Antitumor activity mediated by CpG: the route of administration is critical. J. Immunother. 34:279-88
29. Engelhardt R, Mackensen A, Galanos C. 1991. Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res. 51:2524-30
30. Engelhardt R, Otto F, Mackensen A, et al. 1995. Endotoxin (Salmonella abortus equi) in cancer patients. Clinical and immunological findings. Prog. Clin. Biol. Res. 392:253-61
31. Herr HW, Kemeny N, Yagoda A, et al. 1978. Poly I:C immunotherapy in patients with papillomas or superficial carcinomas of the bladder. Natl. Cancer Inst. Monogr. 325.
32. Levine AS, Sivulich M, Wiernik PH, et al. 1979. Initial clinical trials in cancer patients of polyriboinosinicpolyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer. Cancer Res. 39:1645-50
33. Levy HB, Levine AS. 1981. Antitumor effects of interferon and poly ICLC, and their possible utility as anti-neoplastic agents in man. Tex. Rep. Biol. Med. 41:653-62
34. Butowski N, Lamborn KR, Lee BL, et al. 2009. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J. Neurooncol. 91:183-89
35. Butowski N, Chang SM, Junck L, et al. 2009. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J. Neurooncol. 91:175-82
36. Speiser DE, Lienard D, Rufer N, et al. 2005. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115:739-46
37. Shackleton M, Davis ID, Hopkins W, et al. 2004. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. 4:9
38. Karbach J, Neumann A, Atmaca A, et al. 2011. Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clin. Cancer Res. 17:861-70
39. Adams S, O'Neill DW, Nonaka D, et al. 2008. Immunization of malignant melanoma patients with fulllength NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 181:776-84
40. Prins RM, Soto H, Konkankit V, et al. 2011. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin. Cancer Res. 17:1603-15
41. Wilgenhof S, Van Nuffel AM, Corthals J, et al. 2011. Therapeutic vaccination with an autologousmRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J. Immunother. 34:448-56
42. Koski GK, Koldovsky U, Xu S, et al. 2012. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J. Immunother. 35:54-65
43. DohnalAM, Witt V, HugelH, et al. 2007. Phase I study of tumorAg-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer. Cytotherapy 9:755-70
44. Vonderheide RH. 2007. Prospect of targeting the CD40 pathway for cancer therapy. Clin. Cancer Res. 13:1083-88
45. Advani R, Forero-Torres A, Furman RR, et al. 2009. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J. Clin. Oncol. 27:4371-77
46. Vonderheide RH, Flaherty KT, Khalil M, et al. 2007. Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25:876-83
47. Grover A, Kim GJ, LizeeG, et al. 2006. Intralymphatic dendritic cell vaccination induces tumor antigenspecific, skin-homing T lymphocytes. Clin. Cancer Res. 12:5801-8
48. Yi Q, Szmania S, Freeman J, et al. 2010. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br. J. Haematol. 150:554-64
49. Barth RJ Jr, Fisher DA, Wallace PK, et al. 2010. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin. Cancer Res. 16:5548-56
50. Beatty GL, Chiorean EG, FishmanMP, et al. 2011. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331:1612-16
51. Dudley ME, Wunderlich JR, Robbins PF, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-54
52. Rosenberg SA, Yang JC, Sherry RM, et al. 2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17:4550-57
53. Yee C, Thompson JA, Byrd D, et al. 2002. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99:16168-73
54. Mackensen A, Meidenbauer N, Vogl S, et al. 2006. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 24:5060-69
55. Hunder NN, Wallen H, Cao J, et al. 2008. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358:2698-703
56. Morgan RA, Dudley ME, Wunderlich JR, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126-29
57. Johnson LA, Morgan RA, Dudley ME, et al. 2009. Gene therapy with human andmouseT-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535-46
58. Yvon E, DelVecchio M, Savoldo B, et al. 2009. Immunotherapy ofmetastaticmelanoma using genetically engineered GD2-specific T cells. Clin. Cancer Res. 15:5852-60
59. Burns WR, Zhao Y, Frankel TL, et al. 2010. A high molecular weight melanoma-associated antigenspecific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res. 70:3027-33
60. Dudley ME, Gross CA, Langhan MM, et al. 2010. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin. Cancer Res. 16:6122-31
61. Dudley ME, Wunderlich JR, Yang JC, et al. 2005. Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractorymetastatic melanoma. J. Clin. Oncol. 23:2346-57
62. Dudley ME, Yang JC, Sherry R, et al. 2008. Adoptive cell therapy for patients withmetastaticmelanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26:5233-39
63. Besser MJ, Shapira-Frommer R, Treves AJ, et al. 2010. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes inmetastaticmelanoma patients. Clin. Cancer Res. 16:2646-55
64. Radvanyi LG, Bernatchez C, Zhang M, et al. 2010. Adoptive T-cell therapy for metastatic melanoma: The MD Anderson experience. J. Immunother. 33:863
65. Robbins PF, Morgan RA, Feldman SA, et al. 2011. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29:917-24
66. Lo AS, Ma Q, Liu DL, et al. 2010. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin. Cancer Res. 16:2769-80
67. Kalos M, Levine BL, Porter DL, et al. 2011.Tcells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3:95ra73
68. Porter DL, Levine BL, Kalos M, et al. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365:725-33
69. Wu R, Forget MA, Chacon J, et al. 2012. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J. 18:160-75
70. Restifo NP, Dudley ME, Rosenberg SA. 2012. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12:269-81
71. Robbins PF, El-GamilM, Li YF, et al. 1996. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183:1185-92
72. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. 2005. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202:907-12
73. Besser MJ, Shapira-Frommer R, Treves AJ, et al. 2009. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen inmetastaticmelanoma patients. J. Immunother. 32:415-23
74. Dudley ME, Wunderlich JR, Shelton TE, et al. 2003. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26:332-42
75. Thomas AK, Maus MV, Shalaby WS, et al. 2002. A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin. Immunol. 105:259-72
76. Ye Q, Loisiou M, Levine BL, et al. 2011. Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. J. Transl. Med. 9:131
77. Sharma P, Wagner K, Wolchok JD, et al. 2011. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer 11:805-12
78. Peggs KS, Quezada SA, Allison JP. 2009. Cancer immunotherapy: co-stimulatory agonists and coinhibitory antagonists. Clin. Exp. Immunol. 157:9-19
79. Ise W, Kohyama M, Nutsch KM, et al. 2010. CTLA-4 suppresses the pathogenicity of self antigenspecific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat. Immunol. 11:129-35
80. Wing K, Yamaguchi T, Sakaguchi S. 2011. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol. 32:428-33
81. Corse E, Allison JP. 2012. Cutting edge: CTLA-4 on effector T cells inhibits in trans. J. Immunol. 189(3):1123-27
82. Leach DR, KrummelMF, Allison JP. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-36
83. Hodi FS, O'Day SJ, McDermott DF, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711-23
84. Callahan MK, Wolchok JD, Allison JP. 2010. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin. Oncol. 37:473-84
85. Wolchok JD, Neyns B, Linette G, et al. 2010. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11:155-64
86. Robert C, Thomas L, Bondarenko I, et al. 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364:2517-26
87. Keir ME, Butte MJ, Freeman GJ, et al. 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26:677-704
88. NishimuraH, NoseM, Hiai H, et al. 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141-51
89. NishimuraH, OkazakiT, Tanaka Y, et al. 2001. Autoimmune dilated cardiomyopathy in PD-1 receptordeficient mice. Science 291:319-22
90. Iwai Y, Terawaki S, Honjo T. 2005. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 17:133-44
91. Nomi T, Sho M, Akahori T, et al. 2007. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 13:2151-57
92. Iwai Y, Ishida M, Tanaka Y, et al. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 99:12293-97
93. Brahmer JR, Drake CG, Wollner I, et al. 2010. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28:3167-75
94. Topalian SL, Hodi FS, Brahmer JR, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:2443-54
95. Brahmer JR, Tykodi SS, Chow LQ, et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366:2455-65
96. Liakou CI, Kamat A, Tang DN, et al. 2008. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl. Acad. Sci. USA 105:14987-92
97. Carthon BC, Wolchok JD, Yuan J, et al. 2010. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res. 16:2861-71
98. Sosman JA, Kim KB, Schuchter L, et al. 2012. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366:707-14
99. Hong DS, Vence L, Falchook G, et al. 2012. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency.Clin. Cancer Res. 18:2326-35
100. Wilmott JS, Long GV, Howle JR, et al. 2012. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18:1386-94
101. Dietz AB, Souan L, Knutson GJ, et al. 2004. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104:1094-99
102. Khalili JS, Liu S, Rodríguez-Cruz TG, et al. 2012. Oncogenic BRAF(V600E) promotes stromal cellmediated immunosuppression via induction of interleukin-1 in melanoma. Clin. Cancer Res. 18:5329-40
103. Sumimoto H, Imabayashi F, Iwata T, et al. 2006. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203:1651-56
104. Phan GQ, Yang JC, Sherry RM, et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100:8372-77
105. Weber JS, O'Day S, Urba W, et al. 2008. Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol. 26:5950-56